Table 1.

Demographics and baseline characteristics; absolute (relative) frequency or mean ± SD [95% CI for mean]

	EGb 761® (n = 99)	Pentoxifylline (n = 98)
Women	58 (58.6%)	59 (60.2%)
Age (years)	55.4 ± 10.5	53.1 ± 10.9
	[53.3; 57.5]	[50.9; 55.3]
Weight (kg)	82.6 ± 16.2	77.8 ± 13.7
	[79.4; 85.8]	[75.0; 80.5]
BMI (kg/m2)	27.2 ± 4.4	25.9 ± 3.5
	[26.3; 28.0]	[25.2; 26.5]
Duration of tinnitus (months)	79.6 ± 77.9	84.6 ± 94.5
	[64.0; 95.1]	[65.7; 103.6]
Patients with tinnitus > 2 years	74 (74.7%)	75 (76.5%)
Patients with hearing loss	97 (98.0%)	92 (93.9%)
Mini-TQ	10.5 ± 4.3	11.0 ± 4.3
	[9.62; 11.35]	[10.12; 11.84]
11-Point Box Scale loudness	5.3 ± 1.3	5.6 ± 1.2
	[4.99; 5.52]	[5.37; 5.87]
11-Point Box Scale annoyance	5.2 ± 1.3	5.5 ± 1.3
	[4.95; 5.46]	[5.30; 5.80]
HADS anxiety score	6.2 ± 3.3	5.9 ± 3.5
	[5.53; 6.86]	[5.23; 6.61]
HADS depression score	4.7 ± 3.1	4.4 ± 3.0
	[3.94; 5.26]	[3.40; 4.79]
SDS global impairment	7.5 ± 5.7	8.9 ± 5.9
	[6.31; 8.61]	[7.72; 10.11]